Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Launched by GT MEDICAL TECHNOLOGIES, INC. · Jun 9, 2020

Keywords

ClinConnect Summary

The clinical trial titled "Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)" is studying the real-world outcomes of patients with different types of brain tumors, including glioblastoma and meningioma, who have undergone surgery to remove their tumors and received a special treatment called GammaTiles. The main goal is to see how effective and safe this treatment is from both the doctors' and patients' perspectives.

To participate in this study, patients must have had surgery to remove their brain tumors and have received GammaTiles as part of their treatment. They also need to be able to understand the study and consent to participate. Participants will undergo imaging tests before and after their surgery to help evaluate their condition and the effects of the treatment. It's important for patients to be fluent in English, as some of the assessments will be in that language. This study is currently recruiting participants of all ages and genders, and it aims to gather valuable information that could help improve treatment for future patients with brain tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.
• • 2. Willing and able to provide informed consent and to participate in all evaluations.
• Exclusion Criteria:
• • 1. Inability to undergo pre-operative and post-operative imaging for disease and implant assessment.
• • 2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups.
• • 3. Lack of English language fluency sufficient to allow for completion of neurocognitive and QOL tests (which are in English).

Trial Officials